Table 1.
Patient, disease and transplant characteristics
| Variable | N (%) |
|---|---|
| Number of patients | 34 |
| Age at transplant, years | |
| 2-9 | 14 (41) |
| 10-19 | 11 (32) |
| 20-29 | 7 (21) |
| 30-35 | 2 (6) |
| Sex | |
| Male | 28(82) |
| Female | 6 (18) |
| Performance score | |
| <90% | 10 (29) |
| 90 - 100% | 18 (53) |
| Not reported | 6 (18) |
| Comorbid diseases | |
| CMV infection+pulmonary disease +liver disease | 1 ( 3) |
| CMV infection+pulmonary disease | 1 ( 3) |
| CMV infection only | 14 (41) |
| Comorbid not specified* | 4 (12) |
| No comorbidity | 14 (41) |
| Interval from DC diagnosis to transplant, months | |
| Median (range) | 38 (4-214) |
| <12 | 10 (29) |
| 12-23 | 2 ( 6) |
| 24-35 | 3 ( 9) |
| 36-60 | 7 (21) |
| >60 | 12 (35) |
| Conditioning regimens | |
| Cyclophosphamide + **TBI ≤500 cGy | 6 (17) |
| TBI 200 cGy + fludarabine | 3 ( 9) |
| Melphalan*** + fludarabine | 3 ( 9) |
| Busulfan**** + fludarabine | 1 ( 3) |
| Cyclophosphamide + fludarabine | 4 (12) |
| Cyclophosphamide + busulfan | 6 (18) |
| Cyclophosphamide only | 10 (29) |
| Not reported | 1 ( 3) |
| Graft type | |
| Bone marrow | 24 (71) |
| Peripheral blood | 7 (21) |
| Cord blood | 3 ( 9) |
| Type of donor | |
| HLA-identical sibling | 16 (47) |
| Other relative | 2 ( 6) |
| Matched unrelated donor | 9 (26) |
| Mismatched unrelated donor | 7 (21) |
| Graft-versus-host disease prophylaxis | |
| Ex vivo T-cell depletion | 1 ( 3) |
| CD34 selection | 1 ( 3) |
| Tacrolimus-containing | 5 (15) |
| Cyclosporine-containing | 26 (76) |
| Not reported | 1 ( 3) |
| In vivo T-cell depletion | |
| Anti-thymocyte globulin | 10 (29) |
| Alemtuzumab | 3 ( 9) |
| None | 15 (44) |
| Not reported | 6 (18) |
| Follow-up, surviving patients | 46 (3-116) |
Abbreviations: TBI = total body irradiation
*
Other comorbid includes: organ impairment (n=1), external otitis, peumocystis carinii pneumonia (PCP) infection (n=1), and not specified (n=2)
**
Doses: Cyclophosphamide +TBI ≤ 500 cGy: TBI dose 200 cGy (n=3), 400 cGy (n=1), 450 cGy (n=1) and 500 cGy (n=1)
***
Melphalan dose: 138 mg/m2, 72 mg/m2, 140 mg/m2
****
Busulfan dose: 3mg/kg (n=1)